A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine

Journal of Biomolecular Screening

Volumn 21, Issue 6, 2016, Pages 521-534

  Stern, Andrew M ^a,b   Schurdak, Mark E ^a,b,c   Bahar, Ivet ^a,b,c   Berg, Jeremy M ^a,b   Taylor, D Lansing ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

drug discovery; novel therapeutic strategies; personalized medicine; quantitative systems pharmacology

Indexed keywords

CANCER RESISTANCE; DISEASE COURSE; DRUG DEVELOPMENT; DRUG REPOSITIONING; GENETIC HETEROGENEITY; HUMAN; MATHEMATICAL ANALYSIS; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PHARMACOLOGY; PRIORITY JOURNAL; QUANTITATIVE SYSTEMS PHARMACOLOGY; REVIEW; BIOLOGICAL MODEL; DISEASE EXACERBATION; DRUG DESIGN; DRUG INDUSTRY; TRENDS;

DISEASE PROGRESSION; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MODELS, BIOLOGICAL; PRECISION MEDICINE;

EID: 84975882708     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057116635818     Document Type: Review

References (129)

1. Swinney D. C., The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines. J. Biomol. Screen. 2013, 18, 1186-1192.
2. Zheng W., Thorne N., McKew J. C., Phenotypic Screens as a Renewed Approach for Drug Discovery. Drug Discov. Today. 2013, 18, 1067-1073.
3. Ding G. J., Fischer P. A., Boltz R. C., et al. Characterization and Quantitation of NF-kappaB Nuclear Translocation Induced by Interleukin-1 and Tumor Necrosis Factor-Alpha. Development and Use of a High Capacity Fluorescence Cytometric System. J. Biol. Chem. 1998, 273, 28897-28905.
4. Xu M., Liu K., Swaroop M., et al. delta-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders. J. Biol. Chem. 2012, 287, 39349-39360.
5. Moffat J. G., Rudolph J., Bailey D., Phenotypic Screening in Cancer Drug Discovery: Past, Present and Future. Nat. Rev. Drug Discov. 2014, 13, 588-602.
6. Lee J. A., Uhlik M. T., Moxham C. M., et al. Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy. J. Med. Chem. 2012, 55, 4527-4538.
7. Pammolli F., Magazzini L., Riccaboni M., The Productivity Crisis in Pharmaceutical R&D. Nat. Rev. Drug Discov. 2011, 10, 428-438.
8. Paul S. M., Mytelka D. S., Dunwiddie C. T., et al. How to Improve R&D Productivity: The Pharmaceutical Industry's Grand Challenge. Nat. Rev. Drug Discov. 2010, 9, 203-214.
9. Mullard A., 2014 FDA Drug Approvals. Nat. Rev. Drug Discov. 2015, 14, 77-81.
10. Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation. https://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-fda-final.pdf (. accessed December 16, 2015).
11. Berg J. M., Rogers M. E., Lyster P. M., Systems Biology and Pharmacology. Clin. Pharmacol. Ther. 2010, 88, 17-19.
12. Sorger P. K., Allerheiligen S. R. B., Abernethy D. R., et al. Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms (an NIH White Paper by the QSP Workshop Group). 2011. https://www.nigms.nih.gov/News/reports/Documents/SystemsPharmaWPSorger2011.pdf.
13. Ideker T., Galitski T., Hood L., A New Approach to Decoding Life: Systems Biology. Ann. Rev. Genom. Hum. Genet. 2001, 2, 343-372.
14. Beadle G. W., Tatum E. L., Genetic Control of Biochemical Reactions in Neurospora. Proc. Natl. Acad. Sci. U.S.A. 1941, 27, 499-506.
15. KEGG Pathway Database. http://www.genome.jp/kegg/pathway.html (. accessed December 16, 2015).
16. AlQuraishi M., Koytiger G., Jenney A., et al. A Multiscale Statistical Mechanical Framework Integrates Biophysical and Genomic Data to Assemble Cancer Networks. Nat. Genet. 2014, 46, 1363-1371.
17. Hansen J., Iyengar R., Computation as the Mechanistic Bridge between Precision Medicine and Systems Therapeutics. Clin. Pharmacol. Ther. 2013, 93, 117-128.
18. Wang P., Bahreini A., Gyanchandani R., et al. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions and Cell Free DNA of Breast Cancer Patients. Clin. Cancer Res [Online early access]. DOI: 10.1158/1078-0432.CCR-15-1534. 23, 2015.
19. National Human Genome Research Institute. Biological Pathways Fact Sheet. http://www.genome.gov/27530687 (. accessed December 16, 2015).
20. Zhao S., Iyengar R., Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 505-521.
21. Visser S. A., de Alwis D. P., Kerbusch T., et al. Implementation of Quantitative and Systems Pharmacology in Large Pharma. CPT Pharmacometrics Syst. Pharmacol. 2014, 3, e142.
22. Hood L., Friend S. H., Predictive, Personalized, Preventive, Participatory (P4) Cancer Medicine. Nat. Rev. Clin. Oncol. 2011, 8, 184-187.
23. Jenkins S. L., Ma'ayan A., Systems Pharmacology Meets Predictive, Preventive, Personalized and Participatory Medicine. Pharmacogenomics 2013, 14, 119-122.
24. Azeloglu E. U., Iyengar R., Signaling Networks: Information Flow, Computation, and Decision Making. Cold Spring Harb. Perspect. Biol. 2015, 7, a005934.
25. Carter H., Hofree M., Ideker T., Genotype to Phenotype via Network Analysis. Curr. Opin. in Genet. Dev. 2013, 23, 611-621.
26. Gomes A. P., Blenis J., A Nexus for Cellular Homeostasis: The Interplay between Metabolic and Signal Transduction Pathways. Curr. Opin. Biotechnol. 2015, 34C, 110-117.
27. Krogan N. J., Lippman S., Agard D. A., et al. The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer. Mol. Cell. 2015, 58, 690-698.
28. Jostins L., Ripke S., Weersma R. K., et al. Host-Microbe Interactions Have Shaped the Genetic Architecture of Inflammatory Bowel Disease. Nature 2012, 491, 119-124.
29. Lawrence M. S., Stojanov P., Mermel C. H., et al. Discovery and Saturation Analysis of Cancer Genes across 21 Tumour Types. Nature 2014, 505, 495-501.
30. Morris A. P., Voight B. F., Teslovich T. M., et al. Large-Scale Association Analysis Provides Insights into the Genetic Architecture and Pathophysiology of Type 2 Diabetes. Nat. Genet. 2012, 44, 981-990.
31. Ripke S., Neale B. M., Corvin A., et al. Biological Insights from 108 Schizophrenia-Associated Genetic Loci. Nature 2014, 511, 421-427.
32. Tamborero D., Gonzalez-Perez A., Perez-Llamas C., et al. Comprehensive Identification of Mutational Cancer Driver Genes across 12 Tumor Types. Sci. Rep. 2013, 3, 2650.
33. Van Limbergen J., Radford-Smith G., Satsangi J., Advances in IBD Genetics. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 372-385.
34. Hamburg M. A., Paving the Way for Personalized Medicine. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf (. accessed December 16, 2015).
35. Chakravarti A., Clark A. G., Mootha V. K., Distilling Pathophysiology from Complex Disease Genetics. Cell 2013, 155, 21-26.
36. Ma'ayan A., Jenkins S. L., Goldfarb J., et al. Network Analysis of FDA Approved Drugs and Their Targets. Mt. Sinai J. Med. 2007, 74, 27-32.
37. Barabasi A. L., Gulbahce N., Loscalzo J., Network Medicine: A Network-Based Approach to Human Disease. Nat. Rev. Genet. 2011, 12, 56-68.
38. Hopkins A. L., Network Pharmacology: The Next Paradigm in Drug Discovery. Nat. Chem. Biol. 2008, 4, 682-690.
39. Csermely P., Korcsmaros T., Kiss H. J., et al. Structure and Dynamics of Molecular Networks: A Novel Paradigm of Drug Discovery: A Comprehensive Review. Pharmacol. Ther. 2013, 138, 333-408.
40. Alexopoulos L. G., Saez-Rodriguez J., Cosgrove B. D., et al. Networks Inferred from Biochemical Data Reveal Profound Differences in Toll-Like Receptor and Inflammatory Signaling between Normal and Transformed Hepatocytes. Mol. Cell Proteomics. 2010, 9, 1849-1865.
41. Taylor D. L., A New Vision of Drug Discovery and Development. Eur. Pharmaceut. Rev. 2012, 17.
42. Yang R., Niepel M., Mitchison T. K., et al. Dissecting Variability in Responses to Cancer Chemotherapy through Systems Pharmacology. Clin. Pharmacol. Ther. 2010, 88, 34-38.
43. Potts S. J., Krueger J. S., Landis N. D., et al. Evaluating Tumor Heterogeneity in Immunohistochemistry-Stained Breast Cancer Tissue. Lab Invest. 2012, 92, 1342-1357.
44. Keiser M. J., Setola V., Irwin J. J., et al. Predicting New Molecular Targets for Known Drugs. Nature 2009, 462, 175-181.
45. Wishart D. S., Discovering Drug Targets through the Web. Comp. Biochem. Physiol. Part D Genom. Proteom. 2007, 2, 9-17.
46. Cobanoglu M. C., Liu C., Hu F., et al. Predicting Drug-Target Interactions Using Probabilistic Matrix Factorization. J. Chem. Inf. Model 2013, 53, 3399-3409.
47. Cobanoglu M. C., Oltvai Z. N., Taylor D. L., et al. BalestraWeb: Efficient Online Evaluation of Drug-Target Interactions. Bioinformatics 2015, 31, 131-133.
48. Shamir E. R., Ewald A. J., Three-Dimensional Organotypic Culture: Experimental Models of Mammalian Biology and Disease. Nat. Rev. Mol. Cell Biol. 2014, 15, 647-664.
49. Esch E. W., Bahinski A., Huh D., Organs-on-Chips at the Frontiers of Drug Discovery. Nat. Rev. Drug Discov. 2015, 14, 248-260.
50. Bhatia S. N., Ingber D. E., Microfluidic Organs-on-Chips. Nat. Biotechnol. 2014, 32, 760-772.
51. Wikswo J., Annual Thematic Issue: The Biology and Medicine of Microphysiological Systems [Special Issue]. Exp. Biol. Med. 2014, 239.
52. Orth J. D., Tang Y., Shi J., et al. Quantitative Live Imaging of Cancer and Normal Cells Treated with Kinesin-5 Inhibitors Indicates Significant Differences in Phenotypic Responses and Cell Fate. Mol. Cancer Ther. 2008, 7, 3480-3489.
53. Mohr S. E., Smith J. A., Shamu C. E., et al. RNAi Screening Comes of Age: Improved Techniques and Complementary Approaches. Nat. Rev. Mol. Cell Biol. 2014, 15, 591-600.
54. Shalem O., Sanjana N. E., Zhang F., High-Throughput Functional Genomics Using CRISPR-Cas9. Nat. Rev. Genet. 2015, 16, 299-311.
55. Martz C. A., Ottina K. A., Singleton K. R., et al. Systematic Identification of Signaling Pathways with Potential to Confer Anticancer Drug Resistance. Sci. Signal. 2014, 7, ra121.
56. Gough A. H., Chen N., Shun T. Y., et al. Identifying and Quantifying Heterogeneity in High Content Analysis: Application of Heterogeneity Indices to Drug Discovery. PLoS One. 2014, 9, e102678.
57. Gough A., Lezon T., Faeder J. R., et al. High-Content Analysis with Cellular and Tissue Systems Biology: A Bridge between Cancer Cell Biology and Tissue-Based Diagnostics. In The Molecular Basis of Cancer; 4th ed.; Mendelsohn J., Howley P. M., Israel M. A., et al., Eds.; Saunders/Elsevier: Philadelphia, PA, 2015; Chapter 25, pp 369-392.
58. Almendro V., Marusyk A., Polyak K., Cellular Heterogeneity and Molecular Evolution in Cancer. Annu. Rev. Pathol. 2013, 8, 277-302.
59. Singh D. K., Ku C. J., Wichaidit C., et al. Patterns of Basal Signaling Heterogeneity can Distinguish Cellular Populations with Different Drug Sensitivities. Mol. Syst. Biol. 2010, 6, 369.
60. Albeck J. G., Burke J. M., Aldridge B. B., et al. Quantitative Analysis of Pathways Controlling Extrinsic Apoptosis in Single Cells. Mol. Cell 2008, 30, 11-25.
61. Abraham V. C., Taylor D. L., Haskins J. R., High Content Screening Applied to Large-Scale Cell Biology. Trends Biotechnol. 2004, 22, 15-22.
62. Wen Q., Goldenson B., Silver S. J., et al. Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL. Cell 2012, 150, 575-589.
63. O'Reilly L. P., Long O. S., Cobanoglu M. C., et al. A Genome-Wide RNAi Screen Identifies Potential Drug Targets in a C. elegans Model of Alpha1-Antitrypsin Deficiency. Hum. Mol. Genet. 2014, 23, 5123-5132.
64. Cong F., Cheung A. K., Huang S. M., Chemical Genetics-Based Target Identification in Drug Discovery. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 57-78.
65. Mackinnon A. L., Taunton J., Target Identification by Diazirine Photo-Cross-Linking and Click Chemistry. Curr. Protoc. Chem. Biol. 2009, 1, 55-73.
66. Ong S. E., Schenone M., Margolin A. A., et al. Identifying the Proteins to Which Small-Molecule Probes and Drugs Bind in Cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 4617-4622.
67. Savitski M. M., Reinhard F. B., Franken H., et al. Tracking Cancer Drugs in Living Cells by Thermal Profiling of the Proteome. Science 2014, 346, 1255784.
68. Sutton C. W., The Role of Targeted Chemical Proteomics in Pharmacology. Br. J. Pharmacol. 2012, 166, 457-475.
69. Iyengar R., Zhao S., Chung S. W., et al. Merging Systems Biology with Pharmacodynamics. Sci. Transl. Med. 2012, 4, 126ps127.
70. Janes K. A., Lauffenburger D. A., Models of Signalling Networks: What Cell Biologists Can Gain from Them and Give to Them. J. Cell. Sci. 2013, 126, 1913-1921.
71. Ma'ayan A., Introduction to Network Analysis in Systems Biology. Sci. Signal. 2011, 4, tr5.
72. Faeder J. R., Blinov M. L., Hlavacek W. S., Rule-Based Modeling of Biochemical Systems with BioNetGen. Methods Mol. Biol. 2009, 500, 113-167.
73. Sarioglu A. F., Aceto N., Kojic N., et al. A Microfluidic Device for Label-Free, Physical Capture of Circulating Tumor Cell Clusters. Nat. Methods 2015, 12, 685-691.
74. Dietz H. C., Cutting G. R., Pyeritz R. E., et al. Marfan Syndrome Caused by a Recurrent De Novo Missense Mutation in the Fibrillin Gene. Nature 1991, 352, 337-339.
75. Brooke B. S., Habashi J. P., Judge D. P., et al. Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome. N. Engl. J. Med. 2008, 358, 2787-2795.
76. Loeys B. L., Angiotensin Receptor Blockers: A Panacea for Marfan Syndrome and Related Disorders? Drug Discov. Today. 2015, 20, 262-266.
77. Habashi J. P., Doyle J. J., Holm T. M., et al. Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice through ERK Antagonism. Science 2011, 332, 361-365.
78. Holm T. M., Habashi J. P., Doyle J. J., et al. Noncanonical TGFbeta Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice. Science 2011, 332, 358-361.
79. Neptune E. R., Frischmeyer P. A., Arking D. E., et al. Dysregulation of TGF-Beta Activation Contributes to Pathogenesis in Marfan Syndrome. Nat. Genet. 2003, 33, 407-411.
80. Blair D. R., Lyttle C. S., Mortensen J. M., et al. A Nondegenerate Code of Deleterious Variants in Mendelian Loci Contributes to Complex Disease Risk. Cell 2013, 155, 70-80.
81. Biagioli M., Ferrari F., Mendenhall E. M., et al. Htt CAG Repeat Expansion Confers Pleiotropic Gains of Mutant Huntingtin Function in Chromatin Regulation. Hum. Mol. Genet. 2015, 24, 2442-2457.
82. An M. C., Zhang N., Scott G., et al. Genetic Correction of Huntington's Disease Phenotypes in Induced Pluripotent Stem Cells. Cell Stem Cell 2012, 11, 253-263.
83. Tsvetkov A. S., Arrasate M., Barmada S., et al. Proteostasis of Polyglutamine Varies among Neurons and Predicts Neurodegeneration. Nat. Chem. Biol. 2013, 9, 586-592.
84. Sertbas M., Ulgen K., Cakir T., Systematic Analysis of Transcription-Level Effects of Neurodegenerative Diseases on Human Brain Metabolism by a Newly Reconstructed Brain-Specific Metabolic Network. FEBS Open Bio. 2014, 4, 542-553.
85. Tourette C., Li B., Bell R., et al. A Large Scale Huntingtin Protein Interaction Network Implicates Rho GTPase Signaling Pathways in Huntington Disease. J. Biol. Chem. 2014, 289, 6709-6726.
86. Harrold J. M., Ramanathan M., Mager D. E., Network-Based Approaches in Drug Discovery and Early Development. Clin. Pharmacol. Ther. 2013, 94, 651-658.
87. McKone E. F., Borowitz D., Drevinek P., et al. Long-Term Safety and Efficacy of Ivacaftor in Patients With Cystic Fibrosis Who Have the Gly551Asp-CFTR Mutation: A Phase 3, Open-Label Extension Study (PERSIST). Lancet Respir. Med. 2014, 2, 902-910.
88. Ramsey B. W., Davies J., McElvaney N. G., et al. A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. N. Engl. J. Med. 2011, 365, 1663-1672.
89. Van Goor F., Hadida S., Grootenhuis P. D., et al. Rescue of CF Airway Epithelial Cell Function In Vitro by a CFTR Potentiator, VX-770. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 18825-18830.
90. LaRusch J., Jung J., General I. J., et al. Mechanisms of CFTR Functional Variants That Impair Regulated Bicarbonate Permeation and Increase Risk for Pancreatitis but Not for Cystic Fibrosis. PLoS Genet. 2014, 10, e1004376.
91. Schneider A., Larusch J., Sun X., et al. Combined Bicarbonate Conductance-Impairing Variants in CFTR and SPINK1 Variants Are Associated with Chronic Pancreatitis in Patients without Cystic Fibrosis. Gastroenterology 2011, 140, 162-171.
92. Eder J., Sedrani R., Wiesmann C., The Discovery of First-in-Class Drugs: Origins and Evolution. Nat. Rev. Drug Discov. 2014, 13, 577-587.
93. Giuliano K. A., Haskins J. R., Taylor D. L., Advances in High Content Screening for Drug Discovery. Assay Drug Dev. Technol. 2003, 1, 565-577.
94. Romero L. V., J. M., Alternative Models in Drug Discovery and Development Part II: In Vivo Nonmammalian and Exploratory/Experimental Human Models. In In Vivo Models for Drug Discovery; Vela J. M., Maldonado R., Hamon M., Eds.; Wiley: Weinheim, Germany, 2014; Chapter 3, pp 59-90.
95. Jeremy Wen Q., Yang Q., Goldenson B., et al. Targeting Megakaryocytic-Induced Fibrosis in Myeloproliferative Neoplasms by AURKA Inhibition. Nat. Med. 2015, 21, 1473-1480.
96. Glickman M. S., Sawyers C. L., Converting Cancer Therapies into Cures: Lessons from Infectious Diseases. Cell 2012, 148, 1089-1098.
97. Garraway L. A., Janne P. A., Circumventing Cancer Drug Resistance in the Era of Personalized Medicine. Cancer Discov. 2012, 2, 214-226.
98. Zhao B., Pritchard J. R., Lauffenburger D. A., et al. Addressing Genetic Tumor Heterogeneity through Computationally Predictive Combination Therapy. Cancer Discov. 2014, 4, 166-174.
99. Azam M., Latek R. R., Daley G. Q., Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL. Cell 2003, 112, 831-843.
100. Balbas M. D., Evans M. J., Hosfield D. J., et al. Overcoming Mutation-Based Resistance to Antiandrogens with Rational Drug Design. Elife 2013, 2, e00499.
101. Korpal M., Korn J. M., Gao X., et al. An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide). Cancer Discov. 2013, 3, 1030-1043.
102. Bhang H. E., Ruddy D. A., Krishnamurthy Radhakrishna V., et al. Studying Clonal Dynamics in Response to Cancer Therapy Using High-Complexity Barcoding. Nat. Med. 2015, 21, 440-448.
103. Huang S., Non-Genetic Heterogeneity of Cells in Development: More Than Just Noise. Development 2009, 136, 3853-3862.
104. Altschuler S. J., Wu L. F., Cellular Heterogeneity: Do Differences Make a Difference? Cell 2010, 141, 559-563.
105. Fedele C., Tothill R. W., McArthur G. A., Navigating the Challenge of Tumor Heterogeneity in Cancer Therapy. Cancer Discov. 2014, 4, 146-148.
106. Gerlinger M., Rowan A. J., Horswell S., et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N. Engl. J. Med. 2012, 366, 883-892.
107. Spencer S. L., Gaudet S., Albeck J. G., et al. Non-Genetic Origins of Cell-to-Cell Variability in TRAIL-Induced Apoptosis. Nature 2009, 459, 428-432.
108. Gerdes M. J., Sevinsky C. J., Sood A., et al. Highly Multiplexed Single-Cell Analysis of Formalin-Fixed, Paraffin-Embedded Cancer Tissue. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 11982-11987.
109. Janiszewska M., Liu L., Almendro V., et al. In Situ Single-Cell Analysis Identifies Heterogeneity for PIK3CA Mutation and HER2 Amplification in HER2-Positive Breast Cancer. Nat. Genet. 2015, 47, 1212-1219.
110. Aichler M., Walch A., MALDI Imaging Mass Spectrometry: Current Frontiers and Perspectives in Pathology Research and Practice. Lab Invest. 2015, 95, 422-431.
111. Heselmeyer-Haddad K. M., Berroa Garcia L. Y., Bradley A., et al. Single-Cell Genetic Analysis Reveals Insights into Clonal Development of Prostate Cancers and Indicates Loss of PTEN as a Marker of Poor Prognosis. Am. J. Pathol. 2014, 184, 2671-2686.
112. Bell J. T., Spector T. D., A Twin Approach to Unraveling Epigenetics. Trends Genet. 2011, 27, 116-125.
113. Langevin S. M., Kelsey K. T., The Fate Is Not Always Written in the Genes: Epigenomics in Epidemiologic Studies. Environ. Mol. Mutagen. 2013, 54, 533-541.
114. Cucurull-Sanchez L., Spink K. G., Moschos S. A., Relevance of Systems Pharmacology in Drug Discovery. Drug Discov. Today. 2012, 17, 665-670.
115. Iadevaia S., Lu Y., Morales F. C., et al. Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis. Cancer Res. 2010, 70, 6704-6714.
116. Zinman G., Brower-Sinning R., Emeche C. H., et al. Large Scale Comparison of Innate Responses to Viral and Bacterial Pathogens in Mouse and Macaque. PLoS One. 2011, 6, e22401.
117. Ghiassian S. D., Menche J., Barabasi A. L., A DIseAse MOdule Detection (DIAMOnD) Algorithm Derived from a Systematic Analysis of Connectivity Patterns of Disease Proteins in the Human Interactome. PLoS Comput. Biol. 2015, 11, e1004120.
118. Sharma A., Menche J., Huang C. C., et al. A Disease Module in the Interactome Explains Disease Heterogeneity, Drug Response and Captures Novel Pathways and Genes in Asthma. Hum. Mol. Genet. 2015, 24, 3005-3020.
119. Lin H., Sassano M. F., Roth B. L., et al. A Pharmacological Organization of G Protein-Coupled Receptors. Nat. Methods 2013, 10, 140-146.
120. Liu H., Wang L., Lv M., et al. AlzPlatform: An Alzheimer's Disease Domain-Specific Chemogenomics Knowledgebase for Polypharmacology and Target Identification Research. J. Chem. Inf. Model 2014, 54, 1050-1060.
121. Lamb J., Crawford E. D., Peck D., et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease. Science 2006, 313, 1929-1935.
122. Duan Q., Flynn C., Niepel M., et al. LINCS Canvas Browser: Interactive Web App to Query, Browse and Interrogate LINCS L1000 Gene Expression Signatures. Nucleic Acids Res. 2014, 42, W449-W460.
123. Kim J., Vasu V. T., Mishra R., et al. Bioinformatics-Driven Discovery of Rational Combination for Overcoming EGFR-Mutant Lung Cancer Resistance to EGFR Therapy. Bioinformatics 2014, 30, 2393-2398.
124. Jahchan N. S., Dudley J. T., Mazur P. K., et al. A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors. Cancer Discov. 2013, 3, 1364-1377.
125. Dudley J. T., Sirota M., Shenoy M., et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease. Sci. Transl. Med. 2011, 3, 96ra76.
126. Cooper G. F., Bahar I., Becich M. J., et al. The Center for Causal Discovery of Biomedical Knowledge from Big Data. J. Am. Med. Inform. Assoc. 2015, 22, 1132-1136.
127. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. http://www.nap.edu/catalog/13284/toward-precision-medicine-building-a-knowledge-network-for-biomedical-research (. accessed December 16, 2015).
128. NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial. http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match (. accessed December 16, 2015).
129. Gibson C. C., Zhu W., Davis C. T., et al. Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation. Circulation 2015, 131, 289-299.